Quick Answer
Xenetic Biosciences, Inc. reported Operating Income Loss of -$2.83 million for the year ending 2025.
- Xenetic Biosciences, Inc. showed an increase of +32.6% in Operating Income Loss from 2024 to 2025.
- This data is from Xenetic Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2011 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2011 to 2025), Xenetic Biosciences, Inc.'s Operating Income Loss has declined by 38,335.0%.
- Historical annual values: Fiscal year 2025: -$2.83 million | Fiscal year 2024: -$4.20 million | Fiscal year 2023: -$4.52 million | Fiscal year 2022: -$6.72 million | Fiscal year 2021: -$5.75 million | Fiscal year 2020: -$13.94 million | Fiscal year 2019: -$12.89 million | Fiscal year 2018: -$7.28 million | Fiscal year 2017: -$3.57 million | Fiscal year 2016: -$47.43 million | Fiscal year 2015: -$9.82 million | Fiscal year 2014: -$12.92 million | Fiscal year 2013: -$8.55 million | Fiscal year 2013: -$65.6 thousand | Fiscal year 2012: -$116.7 thousand | Fiscal year 2011: -$7.4 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: